Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Subsidiary eBioscience Signs Distribution Deal With The Binding Site

NEW YORK (GenomeWeb) – Affymetrix today announced through its subsidiary, eBioscience, that the firm has entered into a multi-year distribution agreement with Birmingham, UK-based diagnostic tools supplier The Binding Site.

Under this agreement, The Binding Site has been granted the exclusive rights to distribute eBioscience clinical flow cytometry reagents in the clinical care market, including hospitals and reference labs.

"Our best-in-class full ASR and CE designated immunology and oncology antibody portfolio is a natural complement to the expertise of The Binding Site," Dara Grantham Wright, senior vice president of the eBioscience business at Affymetrix, said in a statement. "With this agreement we strengthen our emphasis on addressing the needs of the growing cancer diagnostics market."

The Binding Site began servicing US customers on Dec. 1 and will start to service customers outside the US on Feb. 15, 2015. The firm supplies reagents and instruments for in vitro diagnostics around the world.

Financial details of the agreement were not disclosed.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.